Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for pancreatic cancer? early trial combines novel drug with chemo

NCT ID NCT06059001

First seen Jan 16, 2026 · Last updated May 20, 2026 · Updated 17 times

Summary

This early-stage trial tests a new drug called OMO-103, given together with standard chemotherapy, in 26 people with advanced pancreatic cancer that has spread. The main goals are to check the safety of the combination and see if it helps shrink tumors. Participants must not have had prior treatment for their advanced disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hospital Gregorio Marañon

    Madrid, Madrid, 28007, Spain

  • Hospital Miguel Servet

    Zaragoza, Zaragoza, 5009, Spain

  • Hospital Regional Universitario de Málaga

    Málaga, Spain, 29010, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, 39008, Spain

  • Hospital Vall d´Hebrón

    Barcelona, Barcelona, 08035, Spain

  • ICO Hopsitalet

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

Conditions

Explore the condition pages connected to this study.